Keyphrases
Bevacizumab
56%
Advanced Solid Tumors
53%
Solid Tumors
46%
Pharmacokinetics
40%
Selinexor
39%
Circulating Tumor DNA (ctDNA)
36%
Monoclonal Antibody
36%
Dose-escalation Study
32%
Overall Survival
32%
Phase I Study
31%
Systematic Meta-analysis
31%
Meta-analysis
31%
Adverse Events
29%
Cell-free DNA (cfDNA)
28%
Tumor
27%
First-in-human
24%
Chemotherapy
23%
Dose-limiting Toxicity
22%
Phase II Trial
21%
Maximum Tolerated Dose
21%
Progression-free Survival
20%
First-in-class
20%
Irinotecan
20%
HER3
20%
Phase II Study
19%
Tolerability
18%
XPO1
18%
Metastatic Tumor
18%
Erlotinib
18%
Olaparib
18%
Exercise Training
18%
Recommended Phase 2 Dose
17%
Antitumor Activity
17%
Stable Disease
16%
Confidence Interval
16%
Recurrent Glioblastoma multiforme
16%
Clinical Activity
16%
Tumor Biopsy
15%
Patients with Advanced Cancer
15%
Serious Adverse Events
15%
Treatment Options
14%
Therapeutic Target
14%
Nausea
14%
Vascular Endothelial Growth Factor
13%
Ovarian Cancer
13%
Combination Therapy
13%
Cancer Patients
13%
Pharmacodynamics
13%
Phase I Trial
13%
Neurofibromatosis Type 2
12%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
69%
Pharmacokinetics
64%
Malignant Neoplasm
57%
Adverse Event
47%
Bevacizumab
43%
Monoclonal Antibody
42%
Biological Marker
39%
Selinexor
36%
Clinical Trial
32%
Progression Free Survival
28%
Pharmacodynamics
27%
Glioblastoma
27%
Disease
26%
Maximum Tolerated Dose
23%
Overall Survival
23%
Phase II Trials
20%
Tolerability
18%
Irinotecan
18%
Erlotinib
18%
Circulating Tumor DNA
18%
Olaparib
18%
Lumretuzumab
18%
Chemotherapy
18%
Nausea
15%
Antitumor Activity
15%
Drug-Drug Interaction
14%
Non Small Cell Lung Cancer
14%
Chemoradiation Therapy
13%
Phase I Trials
13%
Prevalence
12%
Bile Duct Carcinoma
12%
Digestive System Cancer
12%
Multiple Myeloma
12%
Paclitaxel
12%
CYP3A
12%
Cetuximab
12%
Neu Differentiation Factor
11%
Monotherapy
10%
Urokinase Receptor
10%
Combination Therapy
10%
Exportin 1
9%
Gemcitabine
9%
Esophageal Squamous Cell Carcinoma
8%
Squamous Cell Carcinoma
8%
Advanced Cancer
8%
Midazolam
8%
Anemia
8%
Tablet
8%
Melanoma
8%
Medicine and Dentistry
Malignant Neoplasm
45%
Selinexor
33%
Clinical Trial
31%
Neoplasm
28%
Meta-Analysis
24%
Systematic Review
24%
Circulating Tumor DNA
24%
Cell-Free DNA
24%
Adverse Event
24%
Overall Survival
19%
Exercise
18%
Nuclear Export
15%
Arm
14%
Biological Marker
13%
Progression Free Survival
12%
Solid Malignant Neoplasm
12%
Bevacizumab
12%
Ovarian Cancer
12%
CA19-9
11%
Cancer
10%
Patient Referral
9%
Exportin 1
9%
Adenocarcinoma
8%
Anemia
8%
Randomized Controlled Trial
7%
Tumor Biopsy
7%
Cancer Treatment
7%
Biopsy
7%
Disease
7%
Breast Cancer
6%
Systemic Therapy
6%
Colorectal Cancer
6%
Waldenström's Macroglobulinemia
6%
Phosphotransferase
6%
Gastrointestinal Cancer
6%
Platinum-Resistant Ovarian Cancer
6%
Folinic Acid
6%
Docetaxel
6%
Urokinase Receptor
6%
Metastatic Colorectal Cancer
6%
Metastatic Breast Cancer
6%
Neurofibromatosis Type II
6%
Oxaliplatin
6%
Tisotumab Vedotin
6%
Prevalence
6%
Cholangiocarcinoma
6%
Krukenberg Tumor
6%
Molecular Profiling
6%
Chemotherapy Regimens
6%
Erythrocyte Transfusion
6%